StreetInsider.com News Articles

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide

Wed, 26 Aug 2026 10:49:00 -0400

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy.
GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
Failure-free survival (FFS) was 83.9% at 24 weeks and reached 89.4% at 400 mg (78.6% at 200 mg); this FFS also exceeds published 6-month FFS probabilities for all approved steroid-refractory cGvHD therapies.
Complete responses were observed in all but one organ

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide

Wed, 26 Aug 2026 10:49:00 -0400

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy.
GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
Failure-free survival (FFS) was 83.9% at 24 weeks and reached 89.4% at 400 mg (78.6% at 200 mg); this FFS also exceeds published 6-month FFS probabilities for all approved steroid-refractory cGvHD therapies.
Complete responses were observed in all but one organ

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide

Wed, 26 Aug 2026 10:49:00 -0400

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy.
GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
Failure-free survival (FFS) was 83.9% at 24 weeks and reached 89.4% at 400 mg (78.6% at 200 mg); this FFS also exceeds published 6-month FFS probabilities for all approved steroid-refractory cGvHD therapies.
Complete responses were observed in all but one organ

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide

Wed, 26 Aug 2026 10:49:00 -0400

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy.
GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
Failure-free survival (FFS) was 83.9% at 24 weeks and reached 89.4% at 400 mg (78.6% at 200 mg); this FFS also exceeds published 6-month FFS probabilities for all approved steroid-refractory cGvHD therapies.
Complete responses were observed in all but one organ

Form 4 MeiraGTx Holdings plc For: Aug 18 Filed by: Forbes Alexandria

Tue, 18 Aug 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26946064.html

Form 4 MeiraGTx Holdings plc For: Aug 18 Filed by: Forbes Alexandria

Tue, 18 Aug 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26946064.html

Form 144 MeiraGTx Holdings plc Filed by: Forbes Alexandria

Tue, 18 Aug 2026 21:02:00 -0400

si-local-file:///var/storage/secattach/20260818/26946062.html

Form 144 MeiraGTx Holdings plc Filed by: Forbes Alexandria

Tue, 18 Aug 2026 21:02:00 -0400

si-local-file:///var/storage/secattach/20260818/26946062.html

Form SCHEDULE 13G/A MeiraGTx Holdings plc Filed by: Rubric Capital Management LP

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930350.html

Form SCHEDULE 13G/A MeiraGTx Holdings plc Filed by: Rubric Capital Management LP

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930350.html

MeiraGTx Holdings plc (MGTX) PT Raised to $27 at RBC Capital

Fri, 14 Aug 2026 08:41:59 -0400

RBC Capital analyst Lisa Walter raised the price target on MeiraGTx Holdings plc (NASDAQ: MGTX) to $27.00 (from $26.00) while maintaining a Outperform rating.

MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c

Thu, 13 Aug 2026 09:00:31 -0400

MeiraGTx Holdings plc (NASDAQ: MGTX) reported Q2 EPS of $1.71, $2.02 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $321.4 million versus the consensus estimate of $738.6 thousand.

For earnings history and earnings-related data on MeiraGTx Holdings plc (MGTX) click here.

Form S-8 MeiraGTx Holdings plc

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917405.html

Form S-8 MeiraGTx Holdings plc

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917405.html

Form 10-Q MeiraGTx Holdings plc For: Jun 30

Thu, 13 Aug 2026 08:23:00 -0400

si-local-file:///var/storage/secattach/20260813/26917010.html

Form 10-Q MeiraGTx Holdings plc For: Jun 30

Thu, 13 Aug 2026 08:23:00 -0400

si-local-file:///var/storage/secattach/20260813/26917010.html

Form 8-K MeiraGTx Holdings plc For: Aug 13

Thu, 13 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916907.html

Form 8-K MeiraGTx Holdings plc For: Aug 13

Thu, 13 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916907.html

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

Thu, 13 Aug 2026 08:00:00 -0400

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia
Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million
Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition
Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

Thu, 13 Aug 2026 08:00:00 -0400

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia

Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million

Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition

Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

Thu, 13 Aug 2026 08:00:00 -0400

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia

Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million

Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition

Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

Thu, 13 Aug 2026 08:00:00 -0400

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia

Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million

Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition

Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

Tue, 11 Aug 2026 10:30:00 -0400

Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026.
FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).
GV101 is a best-in-class selective ROCK2 inhibitor that increases frataxin protein levels, a therapeutic approach with potential disease-modifying effects in Friedreich's ataxia.
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

Tue, 11 Aug 2026 10:30:00 -0400

Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026.
FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).
GV101 is a best-in-class selective ROCK2 inhibitor that increases frataxin protein levels, a therapeutic approach with potential disease-modifying effects in Friedreich's ataxia.
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

Tue, 11 Aug 2026 10:30:00 -0400

Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026.
FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).
GV101 is a best-in-class selective ROCK2 inhibitor that increases frataxin protein levels, a therapeutic approach with potential disease-modifying effects in Friedreich's ataxia.
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse